Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Breakthrough Designation Standards Revealed (Kind Of)

Executive Summary

Janet Woodcock says agency still cannot detail specific criteria for the popular incentive, but data on breakthrough requests show common characteristics.

You may also be interested in...



Competitive Generic Therapy Designations Growing Despite Lack Of Guidance

US FDA developing document describing program operations, but that has not stopped sponsors from requesting and receiving the breakthrough-like designation. 

Competitive Generic Therapy Designations Growing Despite Lack Of Guidance

US FDA developing document describing program operations, but that has not stopped sponsors from requesting and receiving the breakthrough-like designation. 

Breakthrough Therapies: Maintain The Statistical Rigor, Industry Says

Janssen statistician says FDA should ensure breakthrough sponsors follow the rules just like traditional applicants, although agency statistician experience with designees has been limited.

Related Content

Topics

UsernamePublicRestriction

Register

PS056505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel